You searched for "market"
In conversation with Lawrence Cleary
Lawrence Cleary is an art dealer and an ENT patient. He is also a recipient of an MBE for his contribution towards establishing the first multichannel cochlear implant programme in the UK. In this article he discusses with Katherine Conroy...In conversation with Prof Helge Rask-Andersen: on cell regeneration and treatment of human deafness
Helge Rask-Andersen, head of the inner ear research laboratory at the University of Uppsala in Sweden, has many achievements to his name. He was made an Honorary Member of ENT UK earlier this year. Gerry O’Donoghue caught up with him...In conversation with Chrysa Spyridakou, Robert Nash, Emma Clement, Nish Mehta and Anne GM Schilder
Jaclyn Tan interviews members of the London-based multidisciplinary hearing team, about their insights to auditory neuropathy spectrum disorder, and their vision for the future management of this challenging range of conditions. Auditory neuropathy spectrum disorder (ANSD) describes a wide range...Jameel Muzaffar, Anne Schilder and James O’Hara
In a follow-up to the interview with Anne Schilder back in 2016*, Jameel Muzaffar speaks to Anne and to James O’Hara about the current research landscape in ENT in the UK. *Banerjee A. In conversation with Professor Anne Schilder. ENT...
Management of peritonsillar abscesses – should we be offering a hot tonsillectomy?
Peritonsillar abscesses (PTAs) are one of the most common reasons for patients being referred to ENT services on an emergent basis worldwide. The conventional treatment for adult patients with a PTA in the UK involves needle aspiration or incision and...
Why are we struggling to manage ear pain?
Ear pain can be consumptive. It gnaws like toothache, splits like a headache and can throw off one’s equilibrium. Despite this, we often treat the cause without treating the symptoms. Stoliar and colleagues compared how physicians assess and treat pain...
Bevacizumab, NF2, hearing and age
Introduction NF2-related schwannomatosis (NF2-SWN) is an autosomal dominant disorder leading to the development of schwannomas, meningiomas and spinal cord ependymomas. Younger age is a negative prognostic factor. Treatment includes observation, surgery, radiotherapy and medical therapy with bevacizumab (VEGF monoclonal antibody)....
